欧洲杯竞猜平台-百度百科

Name:Fubin Li
Office Location:280 South Chongqing Road, Room 1008, West #5 Building, Shanghai, China 200025
Telephone:86-21-54592183
Email:fubin.li@sjtu.edu.cn

Education

1997-2001

Fudan University

B.S.

2002-2008

The City University of New York (CUNY)

Ph.D

Career

2009-2012

The Rockefeller University Postdoctoral Associate

2012-2013

The Rockefeller University Research Associate

2013-

Shanghai Jiao Tong University School of Medicine Principal Investigator

2014-

The Rockefeller University Member of the Adjunct Faculty

Research Interests

The lab is mainly interested in two research subjects: (1) how the in vivo activities of cancer immunotherapeutic antibodies are regulated and can be optimized; (2) how B cell development and differentiation are regulated.

Among several ongoing research projects in the lab, we are studying how the interaction between agonistic anti-tumor antibodies and Fcγ receptors impacts on their in vivo activities.

Fcγ receptors have complex interplay with immunoglobulins and regulate both afferent and efferent immune responses. Fcγ receptors are also critical mediators and regulators of therapeutic antibodies’ activities. The research of the lab is focused on the function of Fcγ receptors in immunoregulation and immunotherapy and the underlying molecular mechanism, such as their regulation on B cell response, and on the activities of different classes of antibodies including agonistic antibodies.

Funding

I. National Overseas High Level Young Tanlents Program, team leader;

II. Professor of Special Appointment at Shanghai Institutions of Higher Learning program, team leader；

III. National Natural Science Foundation of China, general program 31370934, The Mechanism of driving the anti-tumor activities of agonistic anti-TNFR superfamily member antibodies by inhibitory Fcgamma receptor, 2014/01 - 2017/12、team leader；

IV. Ministry of Science and Technology of China， program 2014CB943600, Post-transcriptional regulation in lymphocyte development, 2014/01 - 2018/08, team member；

V. National Natural Science Foundation of China, National Science Fund for Excellent Young Scientists program 31422020, Targeted therapeutic molecules based on antibody Fc, 2015/01 - 2017/12, team leader

VI. Shanghai Municipal Education Commission and Shanghai Education Development Foundation, Shu Guang Scholar, Study of the antitumor activity and mechanism of agonistic Fc-CD40L fusion protein, 2015/01-2017/12, team leader

VII. Innovent Biologics, Inc; Hengrui Medicine, Agonistic antibody, Lateral project, 2016/01-2019/08, team leader

VIII. Ministry of Science and Technology of China, 2018ZX10302301-002, The development of diagnosis strategies and products based on specific immune responses to new M. Tuberculosis antigens, 2018/01-2020/12, team leader

IX. Shanghai Science and Technology Committee (STCSM), STCSM-Experimental Animal Grant, The development and application of mice humanized for the target and Fc receptors of monoclonal antibodies, 2018/05-2021/04, team leader

X. National Natural Science Foundation of China, 31870924, The impact and mechanism of action of IgG subclass on the pathogenicity of Dsg1-specific autoantibodies in pemphigus foliaceus, 2019/01-2022/12, team leader

XI. National Natural Science Foundation of China, 31861143030, Targeting TIGIT-PVR interactions for cancer immunotherapy using monoclonal, 2019/01-2021/12, team leader

XII. Shanghai Science and Technology Committee (STCSM), STCSM-Preclinical studies of biological and chemical drugs, Preclinical study of novel agonistic antitumor CD40 antibody, 2019/04-2022/03, team leader

XIII. National Natural Science Foundation of China, 82030043, Elucidation of the modes of action and immunothereapeutic effector pathways of monoclonal anti-OX40 antibodies and optimization of antibody design, 2021/01-2025/12, team leader